Glycemic status and risks of thromboembolism and major bleeding in patients with atrial fibrillation.
Administration, Oral
Aged
Aged, 80 and over
Anticoagulants
/ administration & dosage
Atrial Fibrillation
/ blood
Biomarkers
/ blood
Databases, Factual
Diabetes Mellitus
/ blood
Factor Xa Inhibitors
/ administration & dosage
Female
Glycated Hemoglobin
/ analysis
Hemorrhage
/ chemically induced
Humans
Male
Middle Aged
Registries
Retrospective Studies
Risk Assessment
Risk Factors
Stroke
/ blood
Taiwan
/ epidemiology
Thromboembolism
/ blood
Time Factors
Treatment Outcome
Warfarin
/ administration & dosage
Atrial fibrillation
Direct oral anticoagulants
HbA1c
Ischemic stroke
Major bleeding
Warfarin
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
10 03 2020
10 03 2020
Historique:
received:
25
12
2019
accepted:
24
02
2020
entrez:
12
3
2020
pubmed:
12
3
2020
medline:
26
8
2020
Statut:
epublish
Résumé
Studies specifically examining the association between glycated hemoglobin A1c (HbA1c) levels and ischemic stroke/systemic thromboembolism (IS/SE) risk in atrial fibrillation (AF) patients are limited. Here, we investigated the association between HbA1c levels and the risk of IS/SE, as well as major bleeding, among AF patients with or without oral anticoagulants (OACs). We also compared the effectiveness and safety of warfarin and direct oral anticoagulants (DOACs) in different HbA1c categories. We utilized medical data from a multi-center healthcare provider in Taiwan, which included 34,036 AF patients with serum HbA1c data available within 3 months after AF being diagnosed. Patients were divided into seven study groups according to their HbA1c levels: < 5.4%, 5.4%-5.6%, 5.7%-5.9%, 6.0%-6.4%, 6.5%-6.9%, 7.0%-7.9%, and ≥ 8.0%. The risks of IS/SE and major bleeding were compared among the groups after adjusting for baseline stroke and bleeding risk factors. Compared with the patients with HbA1c level < 5.4%, IS/SE risk significantly increased at HbA1c levels higher than 6.5% [adjusted hazard ratio (HR): 1.20, 95% confidence interval (CI): 1.00-1.43 for HbA1c level 6.5%-6.9%; 1.32, (95% CI 1.11-1.57) for HbA1c level 7.0%-7.9%; and 1.48 (95% CI 1.25-1.76) for HbA1c level ≥ 8.0%]. These results were generally consistent in AF patients without OACs (n = 24,931). However, among 9105 patients receiving OACs, IS/SE risk was not higher for patients having higher HbA1c levels. The risk of major bleeding was comparable across all HbA1c categories. Compared with warfarin, DOACs were associated with lower risks of IS/SE (adjusted HR: 0.61, 95% CI 0.49-0.75) and major bleeding (adjusted HR: 0.30, 95% CI 0.21-0.42) without interactions across different HbA1c categories (all P interactions > 0.05). For AF patients, IS/SE risk significantly increased once HbA1c levels exceeded 6.5%, and OACs may attenuate these associations. Compared with warfarin, DOACs were more effective and safer across broad HbA1c categories. Therefore, in addition to prescribing DOACs when indicated, more aggressive glycemic control to achieve an HbA1c level < 6.5% may be considered for eligible AF patients and should be tested in further prospective studies.
Sections du résumé
BACKGROUND
Studies specifically examining the association between glycated hemoglobin A1c (HbA1c) levels and ischemic stroke/systemic thromboembolism (IS/SE) risk in atrial fibrillation (AF) patients are limited. Here, we investigated the association between HbA1c levels and the risk of IS/SE, as well as major bleeding, among AF patients with or without oral anticoagulants (OACs). We also compared the effectiveness and safety of warfarin and direct oral anticoagulants (DOACs) in different HbA1c categories.
METHODS
We utilized medical data from a multi-center healthcare provider in Taiwan, which included 34,036 AF patients with serum HbA1c data available within 3 months after AF being diagnosed. Patients were divided into seven study groups according to their HbA1c levels: < 5.4%, 5.4%-5.6%, 5.7%-5.9%, 6.0%-6.4%, 6.5%-6.9%, 7.0%-7.9%, and ≥ 8.0%. The risks of IS/SE and major bleeding were compared among the groups after adjusting for baseline stroke and bleeding risk factors.
RESULTS
Compared with the patients with HbA1c level < 5.4%, IS/SE risk significantly increased at HbA1c levels higher than 6.5% [adjusted hazard ratio (HR): 1.20, 95% confidence interval (CI): 1.00-1.43 for HbA1c level 6.5%-6.9%; 1.32, (95% CI 1.11-1.57) for HbA1c level 7.0%-7.9%; and 1.48 (95% CI 1.25-1.76) for HbA1c level ≥ 8.0%]. These results were generally consistent in AF patients without OACs (n = 24,931). However, among 9105 patients receiving OACs, IS/SE risk was not higher for patients having higher HbA1c levels. The risk of major bleeding was comparable across all HbA1c categories. Compared with warfarin, DOACs were associated with lower risks of IS/SE (adjusted HR: 0.61, 95% CI 0.49-0.75) and major bleeding (adjusted HR: 0.30, 95% CI 0.21-0.42) without interactions across different HbA1c categories (all P interactions > 0.05).
CONCLUSION
For AF patients, IS/SE risk significantly increased once HbA1c levels exceeded 6.5%, and OACs may attenuate these associations. Compared with warfarin, DOACs were more effective and safer across broad HbA1c categories. Therefore, in addition to prescribing DOACs when indicated, more aggressive glycemic control to achieve an HbA1c level < 6.5% may be considered for eligible AF patients and should be tested in further prospective studies.
Identifiants
pubmed: 32156277
doi: 10.1186/s12933-020-01005-8
pii: 10.1186/s12933-020-01005-8
pmc: PMC7063754
doi:
Substances chimiques
Anticoagulants
0
Biomarkers
0
Factor Xa Inhibitors
0
Glycated Hemoglobin A
0
hemoglobin A1c protein, human
0
Warfarin
5Q7ZVV76EI
Types de publication
Comparative Study
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
30Références
Pharmacoepidemiol Drug Saf. 2019 May;28(5):593-600
pubmed: 30648314
Eur J Clin Pharmacol. 2015 Jun;71(6):723-732
pubmed: 25911438
Thromb Haemost. 2017 Jun 28;117(7):1230-1239
pubmed: 28597905
JAMA Cardiol. 2017 Apr 1;2(4):442-448
pubmed: 28122078
J Am Coll Cardiol. 2014 May 27;63(20):2141-2147
pubmed: 24657685
Stroke. 1994 Jun;25(6):1157-64
pubmed: 8202973
J Am Heart Assoc. 2018 Aug 7;7(15):e009263
pubmed: 30371232
Chest. 2010 Feb;137(2):263-72
pubmed: 19762550
Diabetes Metab Res Rev. 2017 Mar;33(3):
pubmed: 28029216
Diabetes Care. 2009 Jan;32 Suppl 1:S6-12
pubmed: 19118288
Circ Arrhythm Electrophysiol. 2019 May;12(5):e007030
pubmed: 30995869
Chest. 2018 Nov;154(5):1121-1201
pubmed: 30144419
Diabetes Care. 2014 Jan;37 Suppl 1:S5-13
pubmed: 24357214
Biochimie. 2012 Sep;94(9):1960-7
pubmed: 22627382
Eur Heart J Cardiovasc Pharmacother. 2015 Apr;1(2):86-94
pubmed: 27533976
Stroke. 2015 Apr;46(4):996-1003
pubmed: 25737315
Am Heart J. 2015 Oct;170(4):675-682.e8
pubmed: 26386791
J Am Coll Cardiol. 2018 Jul 17;72(3):255-267
pubmed: 30012318
Int J Cardiol. 2016 Nov 15;223:543-547
pubmed: 27552578
Chest. 2010 Nov;138(5):1093-100
pubmed: 20299623
Heart Rhythm. 2015 May;12(5):886-92
pubmed: 25614249
Cardiovasc Diabetol. 2019 Oct 1;18(1):128
pubmed: 31575379
Diabet Med. 2018 May;35(5):548-556
pubmed: 29438571
J Am Coll Cardiol. 2014 Oct 21;64(16):1658-65
pubmed: 25323252
J Thromb Thrombolysis. 2019 May;47(4):512-519
pubmed: 30565148
N Engl J Med. 2008 Jun 12;358(24):2545-59
pubmed: 18539917
Cerebrovasc Dis. 2008;26(3):310-6
pubmed: 18667812
N Engl J Med. 2011 Sep 15;365(11):981-92
pubmed: 21870978
Am J Cardiovasc Drugs. 2015 Jun;15(3):205-11
pubmed: 25944648
Int J Cardiol. 2015 Oct 1;196:127-31
pubmed: 26093161
Cardiovasc Diabetol. 2019 Jan 28;18(1):12
pubmed: 30691466
JAMA Intern Med. 2014 Jun;174(6):947-53
pubmed: 24733305
Diabetes Care. 2010 Jan;33 Suppl 1:S11-61
pubmed: 20042772
J Diabetes Res. 2019 Dec 6;2019:5158308
pubmed: 31886279
N Engl J Med. 2009 Sep 17;361(12):1139-51
pubmed: 19717844
N Engl J Med. 1976 Aug 19;295(8):417-20
pubmed: 934240
N Engl J Med. 2008 Jun 12;358(24):2560-72
pubmed: 18539916
Cardiovasc Diabetol. 2019 Sep 26;18(1):125
pubmed: 31558158
JAMA. 2001 Jun 13;285(22):2864-70
pubmed: 11401607
Lancet Neurol. 2005 Dec;4(12):821-6
pubmed: 16297840
J Am Coll Cardiol. 2016 Jan 26;67(3):239-47
pubmed: 26796386